fda tirzepatide Grants a New Indication for Obesity Management FDA Drops Latest Statement: Tirzepatide

- ,

doi: 10.3389/fneur.2025.1635441 Received 30 May 2025 Accepted 14 July 2025 Published 30 July 2025 Volume 16 - 2025 Edited by Vassiliy Tsytsarev, University of Maryland, United States Reviewed by Mikhail Inyushin, Central University of the Caribbean, Puerto Rico Megha Mete, Srinath University, India Updates Copyright 2025 Xu, Dong, Yuan, Chen, Shu and Yu

Eating whole foods prepared at home dramatically reduces sodium intake

Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects

GHK-Cu helps your skin repair itself by supporting the creation of essential building blocks, including elastin

In peer-reviewed animal work the concrete numbers are oral doses of roughly 1.442.88 mg/kg given daily to APP/PS1 Alzheimer-model mice over about three months [3] , and low-mg/kg dosing that reversed scopolamine-induced deficits in rodents [1]